Article

Are new therapies in ER-positive breast cancer just the tip of the iceberg?

Author(s):

New therapies for breast cancer are now being based on older therapies such as those that are involved in estrogen blockade. As we understand more about this type of breast cancer, we learn that many of the growth pathways are in fact vast networks. If we block one pathway, cancer may find another way to continue growing. Just this year, Afinitor (everolimus), an mTOR inhibitor, was approved to work along with the aromatase inhibitor exemestane to block multiple pathways in advanced estrogen receptor-positive breast cancer. And this may be just the tip of the iceberg. For more on ER-positive breast cancer updates, stay tuned for the Fall 2012 issue of CURE magazine coming out in September!

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Waldenstrom macroglobulinemia is often slow growing, with high survival but lower quality of life over time, explained researcher Alisha Kimble.
Image of woman.
Image of two doctors and text.
Combining JNJ-1900 with Keytruda may improve distant control of lung cancer, explained by Dr. Jared Weiss.
image of serzan.
Dr. Breelyn Wilky explains that personalized treatments are helping improve outcomes for patients with gastrointestinal stromal tumors.
Image of two doctors with text.
Image of doctors with text.
Imiage of two doctors with text.
Treatment with zanzalintinib plus Opdivo and Opdualag is an option worth exploring in patients with previously untreated clear cell renal cell carcinoma
Related Content